Published in Proc Natl Acad Sci U S A on April 18, 2011
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 1.91
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A (2012) 1.36
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol (2014) 1.32
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A (2015) 1.25
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology (2014) 1.22
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 1.12
Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol (2014) 1.10
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res (2013) 1.09
Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology (2014) 1.09
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect (2012) 0.99
Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 0.99
Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun (2016) 0.95
Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Curr Opin HIV AIDS (2014) 0.89
Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin Exp Immunol (2013) 0.88
Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? Front Immunol (2015) 0.87
Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS One (2012) 0.86
Natural killer cells in patients with severe chronic fatigue syndrome. Auto Immun Highlights (2013) 0.86
Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection. J Virol (2012) 0.84
Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. J Virol (2015) 0.84
CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller. Retrovirology (2012) 0.84
The high cost of fidelity. AIDS Res Hum Retroviruses (2014) 0.83
Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. PLoS One (2013) 0.82
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. Viruses (2015) 0.82
Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol (2012) 0.82
Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women. AIDS Res Hum Retroviruses (2013) 0.79
Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection. Vaccines (Basel) (2013) 0.78
Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes. Hum Vaccin Immunother (2013) 0.78
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. J Infect Dis (2017) 0.78
Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine (2016) 0.77
Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. J Virol (2016) 0.77
Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire. AIDS Res Hum Retroviruses (2013) 0.76
A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies. J Immunol Methods (2016) 0.76
HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies. Pan Afr Med J (2015) 0.76
Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization. Front Microbiol (2016) 0.76
Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. J Virol (2017) 0.75
Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark. AIDS Res Hum Retroviruses (2016) 0.75
The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus. Front Oncol (2016) 0.75
Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters. J AIDS Clin Res (2015) 0.75
Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein. Front Immunol (2017) 0.75
Survivors Remorse: antibody-mediated protection against HIV-1. Immunol Rev (2017) 0.75
Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. JCI Insight (2017) 0.75
A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology (2017) 0.75
Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption. J Virol (2017) 0.75
Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. J Virol (2017) 0.75
HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV. J Virol (2017) 0.75
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol (2009) 1.93
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol (2009) 1.57
Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol (2010) 1.39
The utility of ADCC responses in HIV infection. Curr HIV Res (2008) 1.30
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology (2009) 1.20
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol (2007) 1.05
Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol (2005) 0.99
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology (2008) 0.89
Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol (2009) 0.83
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A (2012) 2.64
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol (2013) 1.95
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol (2009) 1.57
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis (2011) 1.40
Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog (2008) 1.34
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
The utility of ADCC responses in HIV infection. Curr HIV Res (2008) 1.30
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics (2006) 1.21
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol (2013) 1.21
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Chronic cutaneous ulcers secondary to Haemophilus ducreyi infection. Med J Aust (2010) 1.21
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol (2005) 1.15
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 1.15
Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol (2008) 1.14
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med (2011) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10
Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis (2013) 1.10
Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis (2008) 1.09
Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol (2007) 1.07
Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics (2011) 1.05
Quantification of simian immunodeficiency virus cytotoxic T lymphocyte escape mutant viruses. AIDS Res Hum Retroviruses (2008) 1.05
Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol (2007) 1.05
Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine (2005) 1.04
Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine (2005) 1.02
A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano (2009) 1.02
HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol (2012) 1.02
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. AIDS (2007) 1.01
Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol (2011) 1.00
Timing of immune escape linked to success or failure of vaccination. PLoS One (2010) 1.00
CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol (2008) 1.00
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology (2007) 1.00
Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. J Immunol Methods (2012) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 0.99
Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol (2005) 0.99
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
The search for an HIV cure: tackling latent infection. Lancet Infect Dis (2013) 0.98
Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol (2008) 0.98
Natural host genetic resistance to lentiviral CNS disease: a neuroprotective MHC class I allele in SIV-infected macaques. PLoS One (2008) 0.96
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J Immunol (2013) 0.95
Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res (2006) 0.95
Does cytolysis by CD8+ T cells drive immune escape in HIV infection? J Immunol (2010) 0.94
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J Virol (2006) 0.94
Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology (2011) 0.92
Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin. J Biol Chem (2010) 0.92
Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine (2005) 0.92
Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol (2011) 0.92
The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS (2015) 0.91
HIV-specific antibody immunity mediated through NK cells and monocytes. Curr HIV Res (2013) 0.90